Incremental associations of pharmacological components in heart failure with mildly reduced or preserved ejection fraction: a systematic review and component network meta-analysis

We conducted a component network meta-analysis (CNMA) of phase 3/4 randomized trials to evaluate incremental effects of pharmacological therapies in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF; LVEF > 40%). MEDLINE, Embase, and Cochrane were searched through 1 August 2025 (updated 30 March 2026). We performed an additive CNMA evaluating cardiovascular death or first heart failure hospitalization (HFH) and assessed certainty of evidence. Twenty-four trials and five secondary reports were included. The primary network was sparse (10 trials, 12 regimens), constraining interaction detection and component stability. Incretin-based interventions (pooling semaglutide and tirzepatide, iHR 0.69, 95% CI 0.53–0.91), SGLT-2 inhibitors (0.80, 0.74–0.88), ARNis (0.82, 0.68–0.99), and MRAs (0.89, 0.81–0.98) showed significant component associations, driven principally by fewer HFHs. No drug class significantly reduced mortality. SGLT-2 inhibitors and MRAs remained significant across sensitivity analyses except LVEF ≥ 50%, with SGLT-2 inhibitors most precise. ARNi benefits lost significance under stricter background therapy thresholds (>60%) and contemporary trial restrictions. Evidence for incretins was low-certainty and sensitive to trial selection. SGLT-2 inhibitors and MRAs provide the most robust incremental benefit, while evidence for other drug classes remains context-dependent. These findings should guide research priorities rather than define combination regimens. http://www.crd.york.ac.uk PROSPEROidentifier is CRD420251107058.

Authors

Publication Details

Journal
Figshare
Published
2026-11-21
DOI
https://doi.org/10.6084/m9.figshare.35081792
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Incremental associations of pharmacological components in heart failure with mildly reduced or preserved ejection fraction: a systematic review and component network meta-analysis

Flory Tsobo Muanda, Manik Chhabra, Mohammad Ali Omrani, Fatemeh Ahmadi et al.
Figshare
Heart Failure Treatment and Management
article

Incremental associations of pharmacological components in heart failure with mildly reduced or preserved ejection fraction: a systematic review and component network meta-analysis

Flory Tsobo Muanda, Manik Chhabra, Mohammad Ali Omrani, Fatemeh Ahmadi, Atefeh Jafari, Lujain Ez Eddin, Bala Swetha Baskaran, Kristin Clemens, Sheikh Abdullah, Mê-Linh Lê
article en

Abstract

We conducted a component network meta-analysis (CNMA) of phase 3/4 randomized trials to evaluate incremental effects of pharmacological therapies in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF; LVEF > 40%). MEDLINE, Embase, and Cochrane were searched through 1 August 2025 (updated 30 March 2026). We performed an additive CNMA evaluating cardiovascular death or first heart failure hospitalization (HFH) and assessed certainty of evidence. Twenty-four trials and five secondary reports were included. The primary network was sparse (10 trials, 12 regimens), constraining interaction detection and component stability. Incretin-based interventions (pooling semaglutide and tirzepatide, iHR 0.69, 95% CI 0.53–0.91), SGLT-2 inhibitors (0.80, 0.74–0.88), ARNis (0.82, 0.68–0.99), and MRAs (0.89, 0.81–0.98) showed significant component associations, driven principally by fewer HFHs. No drug class significantly reduced mortality. SGLT-2 inhibitors and MRAs remained significant across sensitivity analyses except LVEF ≥ 50%, with SGLT-2 inhibitors most precise. ARNi benefits lost significance under stricter background therapy thresholds (>60%) and contemporary trial restrictions. Evidence for incretins was low-certainty and sensitive to trial selection. SGLT-2 inhibitors and MRAs provide the most robust incremental benefit, while evidence for other drug classes remains context-dependent. These findings should guide research priorities rather than define combination regimens. http://www.crd.york.ac.uk PROSPEROidentifier is CRD420251107058.

Figshare
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Incremental associations of pharmacological components in heart failure with mildly reduced or preserved ejection fraction: a systematic review and component network meta-analysis — Flory Tsobo Muanda, Manik Chhabra, et al. · Figshare (2026) | TGRS Research Map | TGRS